Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Testicular Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
21 drugs · 23 active trials
0 drugs · 0 active trials
no drug at this stage
3 drugs · 2 active trials
Outside the funnel: Phase not stated 5. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Etoposide | Approved | Phase 3 | 2 | 1 | 3 | 10 | 1 | US | Feb 13, 2026 | Nov 3, 2003 |
| Ifosfamide | Approved | Phase 2 | 0 | 0 | 0 | 2 | 1 | US | Aug 14, 1987 | Nov 5, 2007 |
| Dactinomycin | Approved | — | 0 | 0 | 0 | 0 | 1 | US | Nov 9, 2017 | — |
| Carboplatin | Phase 3 | Phase 3 | 3 | 1 | 1 | 8 | 0 | — | — | 2003-08 |
| Cisplatin | Phase 3 | Phase 3 | 3 | 2 | 2 | 5 | 0 | — | — | Nov 3, 2003 |
| Cyclophosphamide | Phase 3 | Phase 3 | 1 | 1 | 2 | 10 | 0 | — | — | 1988-03 |
| Doxorubicin | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Methotrexate | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 1988-03 |
| Prednisone | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Vincristine | Phase 3 | Phase 3 | 1 | 1 | 2 | 4 | 0 | — | — | 2004-12 |
| Cytarabine | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | Feb 29, 2012 |
| Dexamethasone | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 2003-08 |
| Leucovorin | Phase 3 | Phase 3 | 1 | 1 | 2 | 3 | 0 | — | — | 2009-06 |
| Bleomycin | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Nov 3, 2003 |
| Daunorubicin | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Mercaptopurine | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Pegaspargase | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Thioguanine | Phase 3 | Phase 3 | 1 | 1 | 2 | 2 | 0 | — | — | Feb 29, 2012 |
| Blinatumomab | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Calaspargase Pegol | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Inotuzumab Ozogamicin | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Prednisolone | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Oct 31, 2019 |
| Dasatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2008-10 |
| Clofarabine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Feb 29, 2012 |
| Ipilimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2003-04 |
| Paclitaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2007-09 |
| Veliparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jun 20, 2011 |
| Aspirin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 28, 2025 |
| Nivolumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2017 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Rituximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2003-01 |
| Fludarabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 1999-11 |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2010-05 |
| Busulfan | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 1988-03 |
| Gemcitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2003-08 |
| Melphalan | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Jun 29, 2006 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Feb 26, 2007 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-05 |
| Bendamustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-07 |
| Brentuximab Vedotin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 5, 2013 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 28, 2016 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-10 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-12 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-03 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-06 |
| Cabazitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-06 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 2, 2009 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-06 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-06 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.